PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES

• Adam Olszewski,
• David Kahn,
• Brian Yoo,
• Zhe Nie,
• Goran Krilov,
• Joanne Tan,
• Hamish Wright,
• Daniel Weiss,
• Wu Yin,
• Karen Akinsanya

Affiliations

Adam Olszewski

1 Lifespan Cancer Institute at Rhode Island Hospital

David Kahn

2 South Florida Cancer Care

Brian Yoo

3 Schrodinger

Zhe Nie

3 Schrodinger

Goran Krilov

3 Schrodinger

Joanne Tan

3 Schrodinger

Hamish Wright

3 Schrodinger

Daniel Weiss

3 Schrodinger

Wu Yin

3 Schrodinger

Karen Akinsanya

3 Schrodinger